title: Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.
abstract: OBJECTIVE
  CHOICE (CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy) assessed patterns of exenatide bid and initial insulin therapy usage in clinical practice in six European countries and evaluated outcomes during the study.
  
  
  METHODS
  CHOICE was a 24-month, prospective, noninterventional observational study. Clinical and resource use data were collected at initiation of first injectable therapy (exenatide bid or insulin) and at regular intervals for 24 months. Costs were evaluated from the national health care system perspective at 2009 prices.
  
  
  RESULTS
  A total of 2515 patients were recruited. At the 24-month analysis, significant treatment change had occurred during the study in 42.2% of 1114 eligible patients in the exenatide bid cohort and 36.0% of 1274 eligible patients in the insulin cohort. Improvements in glycemic control were observed over the course of the study in both cohorts (P < 0.001 for both), but mean weight was reduced in the exenatide bid cohort (P < 0.001) and increased in the insulin cohort (P < 0.001) by 24 months. Across all countries, total per patient health care costs for the 24 months post baseline were €3997.9 in the exenatide bid cohort and €3265.5 in the insulin cohort (€1791.9 versus €2465.5 due to costs other than those of injectable therapy). When baseline direct cost and patients' and disease characteristics were controlled for, mean direct costs differed by country (P < 0.0001), irrespective of treatment initiated, and the mean cost difference between treatments varied by country (P < 0.0001).
  
  
  CONCLUSIONS
  Much of the higher mean cost of exenatide bid, compared with insulin, therapy was compensated for by lower mean costs of other health service utilization. Costs associated with exenatide bid or insulin initiation varied across countries, highlighting the need to avoid generalization of resource use and cost implications of a particular therapy when estimated in specific country settings.
authors.affiliation: Eli Lilly, Helsinki, Finland; , Germany.
authors.forename: Urpo
authors.initials: U
authors.lastname: Kiiskinen
authors.forename: Stephan
authors.initials: S
authors.lastname: Matthaei
authors.forename: Matthew
authors.initials: M
authors.lastname: Reaney
authors.forename: Chantal
authors.initials: C
authors.lastname: Mathieu
authors.forename: Claes-Göran
authors.initials: CG
authors.lastname: Ostenson
authors.forename: Thure
authors.initials: T
authors.lastname: Krarup
authors.forename: Michael
authors.initials: M
authors.lastname: Theodorakis
authors.forename: Jacek
authors.initials: J
authors.lastname: Kiljański
authors.forename: Carole
authors.initials: C
authors.lastname: Salaun-Martin
authors.forename: Hélène
authors.initials: H
authors.lastname: Sapin
authors.forename: Bruno
authors.initials: B
authors.lastname: Guerci
keywords: exenatide; health care costs; injectable therapy; insulin; resource use; type 2 diabetes mellitus